Osimertinib dose-reduction issues in EGFR-mutated metastatic NSCLC

Lung Cancer 2026

View at publisher

Authors: Tian Xia, Yi Zhang, Liang Zheng

DOI: 10.1016/j.lungcan.2026.109313

Cited by: 0

References: 6

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment HER2/EGFR in Cancer Research

References 6